BeiGene has made the decision to end the clinical development program for ociperlimab (BGB-A1217) for the treatment of lung cancer.

BeiGene, which plans to change its name to BeOne Medicines, is a global oncology company that is discovering and developing innovative treatments that are more accessible and affordable to cancer ...

ADRs came under pressure in the premarket on Thursday after the company announced its decision to halt a clinical program targeting its antibody therapy ociperlimab (BGB-A1217) in lung cancer in ...

The US biotech has just agreed a $2.7 billion deal with BeiGene that will give it a rapid route to rolling out its cancer drugs in China – both approved and in the development pipeline – as it ...

California-based biotech BeiGene has terminated the clinical development programme for its lung cancer therapy ociperlimab, after an independent committee ruled that it was unlikely to meet its ...

Analysts have set 12-month price targets for BeiGene, revealing an average target of $330.25, a high estimate of $348.00, and ...

Beigene (NASDAQ:ONC – Get Free Report) is one of 1,072 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Beigene ...

We’ve lowered our fair value estimate of Snap-on stock. We sell different types of products and services to both investment professionals and individual investors. These products and services ...

The firms will use nFerence's Agentic AI platform to analyze real-world treatment patterns in 700 patients' charts and inform personalized care.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BeiGene has decided to end the clinical development program for ociperlimab (BGB-A1217) as a treatment for lung cancer.